Rong-qiang Liu

Title: Innovations of Rong-qiang Liu

Introduction

Rong-qiang Liu is a notable inventor based in Kendall Park, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific cancer pathways. With a total of five patents to his name, Liu's work has the potential to impact the treatment of proliferative disorders.

Latest Patents

Among his latest patents, Liu has developed fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors. The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R, R, R, R, R, A, A, A, A, and A are as defined herein. The compounds of formula I or II exhibit ALK and/or c-Met inhibitory activity, making them valuable in the treatment of proliferative disorders.

Career Highlights

Throughout his career, Liu has worked with prominent companies in the pharmaceutical industry, including Cephalon, Inc. and Schering-Plough Corporation. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Liu has collaborated with several professionals in his field, including Kevin D McCormick and Christopher W Boyce. These collaborations have likely enhanced his research and development efforts, leading to successful innovations.

Conclusion

Rong-qiang Liu's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of serious health conditions.